Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial

Archives of Internal Medicine

Volumn 161, Issue 2, 2001, Pages 218-227

  Wadden, Thomas A ^a   Berkowitz, Robert I ^a   Sarwer, David B ^a   Prus Wisniewski, Richard ^a   Steinberg, Carrie ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIBUTRAMINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DIETARY INTAKE; FEMALE; HEALTH STATUS; HUMAN; KINESIOTHERAPY; LIFESTYLE; MAJOR CLINICAL STUDY; OBESITY; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; SELF ESTEEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 0035931331     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.2.218     Document Type: Article

References (42)

1. Current and potential drugs for treatment of obesity
2. Sibutramine - A review of clinical efficacy
3. A double-blind randomized placebo-controlled trial of sibutramine
4. Sibutramine reduces food intake in non-dieting women with obesity
5. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
6. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
7. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial
8. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study
9. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1 -year randomized double-blind study
10. Sibutramine produces dose-related weight loss
11. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
12. Long-term pharmacotherapy in the management of obesity
13. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report
14. Mechanisms of action in cognitive-behavioral and pharmacological interventions for obesity and bulimia nervosa
15. Report on the NIH workshop on pharmacologic treatment of obesity
16. Behavior therapy and pharmacotherapy for obesity
17. Sequencing of behavior therapy and pharmacotherapy for obesity
18. Long-term weight control study, I (weeks 0 to 34): The enhancement of behavior modification, caloric restriction, and exercise by fenfluarmine plus phentermine versus placebo
19. Exercise in the treatment of obesity: Effects of four interventions on body composition, resting energy expenditure, appetite, and mood
20. Strengthening behavioral interventions for weight loss: A randomized trial of food provision and monetary incentives
21. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes
22. Behavioral treatment of obesity: New approaches to an old disorder
23. Binge eating disorder: Current knowledge and future directions
24. Behavioral approaches to the treatment of obesity
25. Relation of weight loss to changes in serum lipids and lipoproteins in obese women
26. Behavioural treatment of the overweight patient
27. Effect of degree of weight loss on health benefits
28. Beneficial effects of modest weight loss
29. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
30. What characterizes successful weight maintainers?
31. Lifestyle modification in the pharmacologic treatment of obesity: A pilot investigation of a potential primary care approach
32. Very low-calorie diets
33. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations
34. Valvular heart disease associated with fenfluramine-phentermine